Xencor (XNCR) FDA catalyst dates

FreeBioList tracks 6 upcoming catalysts for Xencor (XNCR, listed on Nasdaq). They cover 5 programmes: XmAb819 (Advanced clear cell renal cell carcinoma (ENPP3 x CD3)), Plamotamab (Rheumatoid arthritis (CD20 x CD3)), XmAb657 (B-cell autoimmune disease (CD19 x CD3)) and XmAb942 (Ulcerative colitis (anti-TL1A) — blinded interim analysis; Ulcerative colitis (12-week induction)), and 1 more.

First on the list: the Phase 1 readout for XmAb819 (Advanced clear cell renal cell carcinoma (ENPP3 x CD3)), guided by the company to Oct 2026. The furthest-out event tracked is H2 2027. By stage, the upcoming rows are 3 Phase 1 readouts, 1 Phase 1B readout and 2 Phase 2 readouts.

All 6 rows link to SEC filings (8-K or 6-K). All have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.

Background reading: Clinical trial phases explained: Phase 1 to Phase 4.

Company ▾	Drug ▾	Effect / indication	Next catalyst ▾	Phase / type ▾	Status ▾	Source	Options
Xencor XNCR · Nasdaq	XmAb819	Advanced clear cell renal cell carcinoma (ENPP3 x CD3)	Oct 2026 company guidance	Phase 1 readout	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing states "Phase 1 results for patients with advanced ccRCC were accepted for a proffered paper oral presentation at the ESMO Congress 2026" (Madrid, 23-27 October). Conference-dated rather than quarter-guided. Source: 8-K exhibit 99.1, filed 05 Aug 2026 · verified 12 Sep 2026
Xencor XNCR · Nasdaq	Plamotamab	Rheumatoid arthritis (CD20 x CD3)	H2 2026 company guidance	Phase 1B readout	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing states Xencor "plans to provide an update on progress achieved in the Phase 1b study of plamotamab in RA in 2H26." Source: 8-K exhibit 99.1, filed 05 Aug 2026 · verified 12 Sep 2026
Xencor XNCR · Nasdaq	XmAb657	B-cell autoimmune disease (CD19 x CD3)	H2 2026 company guidance	Phase 1 readout	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing states Xencor "plans to provide an update on progress achieved in the Phase 1 study of XmAb657 in 2H26." Source: 8-K exhibit 99.1, filed 05 Aug 2026 · verified 12 Sep 2026
Xencor XNCR · Nasdaq	XmAb942	Ulcerative colitis (anti-TL1A) — blinded interim analysis	Late 2026 company guidance	Phase 2 readout	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing states enrolment "continue[s] to support a XENITH-UC blinded interim analysis around year-end 2026." Source: 8-K exhibit 99.1, filed 05 Aug 2026 · verified 12 Sep 2026
Xencor XNCR · Nasdaq	XmAb412	Inflammatory disease (TL1A x IL23p19)	H1 2027 company guidance	Phase 1 readout	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing states Xencor "initiated a first-in-human study of XmAb412 in the third quarter of 2026 and plans to present initial data from the study in 1H27." Source: 8-K exhibit 99.1, filed 05 Aug 2026 · verified 12 Sep 2026
Xencor XNCR · Nasdaq	XmAb942	Ulcerative colitis (12-week induction)	H2 2027 company guidance	Phase 2 readout	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing guides "reaching the primary endpoint of the 12-week induction period in 2H27." Source: 8-K exhibit 99.1, filed 05 Aug 2026 · verified 12 Sep 2026

Company ▾

Drug ▾

Effect / indication

Next catalyst ▾

Phase / type ▾

Status ▾

Source

Options

Xencor XNCR · Nasdaq

XmAb819

Advanced clear cell renal cell carcinoma (ENPP3 x CD3)

Oct 2026
company guidance

Phase 1 readout

Verified

8-K exhibit 99.1 ↗

Yes

Xencor XNCR · Nasdaq

Plamotamab

Rheumatoid arthritis (CD20 x CD3)

H2 2026
company guidance

Phase 1B readout

Verified

8-K exhibit 99.1 ↗

Yes

Xencor XNCR · Nasdaq

XmAb657

B-cell autoimmune disease (CD19 x CD3)

H2 2026
company guidance

Phase 1 readout

Verified

8-K exhibit 99.1 ↗

Yes

Xencor XNCR · Nasdaq

XmAb942

Ulcerative colitis (anti-TL1A) — blinded interim analysis

Late 2026
company guidance

Phase 2 readout

Verified

8-K exhibit 99.1 ↗

Yes

Xencor XNCR · Nasdaq

XmAb412

Inflammatory disease (TL1A x IL23p19)

H1 2027
company guidance

Phase 1 readout

Verified

8-K exhibit 99.1 ↗

Yes

Xencor XNCR · Nasdaq

XmAb942

Ulcerative colitis (12-week induction)

H2 2027
company guidance

Phase 2 readout

Verified

8-K exhibit 99.1 ↗

Yes

Companies working on related conditions

Arcus Biosciences (RCUS)First-line clear cell renal cell carcinoma; Second-line clear cell renal cell carcinoma; First-line metastatic pancreatic ductal adenocarcinoma
Spyre Therapeutics (SYRE)Ulcerative colitis; Rheumatoid arthritis; Psoriatic arthritis; Axial spondyloarthritis
MacroGenics (MGNX)Advanced solid tumours (B7-H3 ADC); Advanced solid tumours (ADAM9 ADC); Clear cell gynaecologic cancer (PD-1 x CTLA-4)
Allogene Therapeutics (ALLO)Autoimmune disease (allogeneic CD19/CD70 CAR-T); First-line large B-cell lymphoma consolidation
Celldex Therapeutics (CLDX)Chronic spontaneous urticaria (anti-KIT); Atopic dermatitis; Chronic spontaneous urticaria
Climb Bio (CLYM)IgA nephropathy / autoimmune (CD19 antibody)

Also due in Q4 2026

MBX Biosciences (MBX)Phase 1 readout for MBX 4291, Q4 2026
Enanta Pharmaceuticals (ENTA)Phase 1 readout for EDP-978, Q4 2026
Arvinas (ARVN)Phase 1 readout for ARV-102, Oct 2026
Aprea Therapeutics (APRE)Phase 1 readout for APR-1051, Q4 2026
Neumora Therapeutics (NMRA)Phase 1 readout for NMRA-511, Q4 2026
Kyverna Therapeutics (KYTX)Phase 1 readout for Miv-cel (mivotacel), Q4 2026